41616-97-1

Upstream product

• 2941-69-7 5-methoxy-2-methylbenzo[d]thiazole 
• 75-03-6 ethyl iodide 

Downstream Products

• 719277-26-6 TG003 
• 84626-20-0 3,3'-diethyl-5,5'-dimethoxy-11-methyl-10,12-trimethylenethiatricarbocyanine iodide 
• 34543-63-0 1,5-bis-(3-ethyl-5-methoxy-benzothiazol-2-yl)-2-phenyl-pentamethinium; iodide 

Relevant academic research and scientific papers

INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF

Provided herein are compounds which are CDC2-Like Kinase (CLK) inhibiting compounds and methods of use thereof. The CLK-inhibiting compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and d

Modulators of CDC2-like kinases (CLKS) and methods of use thereof

Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a Clk modulating compound in combination with another therapeutic agent.

Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction

The present invention provides a composition of treating, preventing abnormal splicing caused by the excessive kinase induction, which comprises TG003 and a method using the same of treating, preventing abnormal splicing caused by the excessive kinase induction.